Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) ...
Phase 1b trial shows 40% response rate for onvansertib plus paclitaxel in metastatic triple-negative breast cancer, with manageable toxicity. Cardiff Oncology, Inc. announced promising results from a ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- An ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback